Singapore markets close in 3 hours 5 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.77-0.96 (-1.42%)
At close: 4:00PM EDT
Sign in to post a message.
  • j
    jrward
    Finally we get to the results!! All these negative vibes have had their day! Investors look only for results and yes tomorrow will bring a beat and an upbeat conference call with all that is in the pipeline. GILD is past the half time moving out of the just HIV scenario that’s why they brought in the new CEO he’s on a long term plan that will bring this into the $100s easy and if a buy out $140 !!
  • S
    Sharbe
    "how do you like me now", says O'Day as the stock craters this morning. He could care less about you shareholders as long as he gets paid. Human nature.
  • S
    SoapySmith
    Wow why the big down day ?
  • R
    Robert
    Thank you Mr ODay, your vision and efforts will guild us to the promised land.
    Long, strong, not a short with a bong.
  • C
    Cnote
    2 straight earnings beat…75 comin
  • M
    Madmonty
    Got muted, try it another way, consensus 1.73, earnings whisper at 1.85
  • K
    Kjinman
    Ok so thankyou for the input from various posters like Itsjustmyopinion

    So, looking at NON-GAAP, we have conservative earnings of $6.90 a share. With 1.25B shares outstanding, that would be earnings of 8.625B in earnings

    For our industry, standard multiples would be 25-40 times their earnings, so let’s say 30.

    30 x 8.625B = 258.75B

    258.75B divided by the 1.25B shares outstanding = $207

    So, there you have it, a fair MC for this company, as it stands, is 258B and, currently, it is at 85B.

    Fair share price is $207 and currently trades at $67.63. using same method, Pfizer is priced at $64.

    At a buyout of $140, which is approx. 175B, that would be a 30% discount to the real value of 258B.

    Another quick calculation is the EBITDA margin (EBITDA/Revenue). In large pharmas, 19% is average. GILD is at 50%.

    Thanks all!
  • G
    Gary
    Going out to buy a case of Kettle One today. Earnings call this week and thats the only thing that gets me thru that call !!!! O' Day's almost as hard to listen to as 46. Been a holder of this stock for many years and can't express my frustration enough with this management team that does nothing to promote the company.
    Good luck to all.
  • j
    jerry
    The last two years has been a disaster for shareholders we’ve got to get new management that knows what they’re doing, that’s the only hope we have.
  • I
    ItsJustMyOpinion
    From Sept. 2020 Press Release: Trodelvy

    Compelling Strategic Benefits

    Rapidly Expanding Trodelvy’s Benefit for Patients Globally: After closing Gilead intends to initiate numerous additional mid- and late-stage studies in the near term to determine which patients will benefit from Trodelvy as both a monotherapy or in combination with other products. Gilead brings commercial, medical, regulatory and manufacturing expertise, which will help rapidly advance Trodelvy through development and reach additional patients. Gilead will also bring to Immunomedics an established infrastructure and operations in Europe and Japan to support the launch of Trodelvy in those regions, pending approval. After closing, Gilead will retain global rights to Trodelvy outside of greater China, South Korea and certain Southeast Asian countries.

    Trodelvy is Foundational to Gilead’s Oncology Franchise: Trodelvy will bring to Gilead a cornerstone product that broadens and deepens the company’s solid tumor pipeline, building on current marketed products and late-stage clinical candidates for patients with hematological malignancies at Kite and Gilead, including Yescarta®, Tecartus® and magrolimab.

    Trodelvy is approved as a third-line treatment for mTNBC and has shown promise for earlier stages of the disease. TNBC represents approximately 15 to 20 percent of all breast cancer cases and is generally considered the most aggressive form of breast cancer. HR+/HER2- breast cancer accounts for more than 70 percent of all breast cancers.

    Accelerates Gilead’s Revenue and EPS Growth: Trodelvy was launched in May of 2020 and has significant commercial potential in mTNBC and other solid tumors. In addition to immediately accelerating Gilead’s revenue growth, the acquisition of Immunomedics is expected to be neutral to accretive to Gilead’s non-GAAP EPS in 2023 and significantly accretive thereafter.
  • T
    Tealk
    Did Biontech and Moderna donate any vaccines? How do their share prices compare with GILD?
  • I
    ItsJustMyOpinion
    Looking forward to what Gilead reports about their cancer products. BMY showed some solid numbers in that area.
    ***Bristol Myers Squibb (BMY) topped third-quarter estimates on Wednesday as two cancer treatments helped drive growth, but BMY stock toppled to a 16-month low as Revlimid generics wait in the wings.

    The company credited cancer drugs Revlimid and Opdivo, as well as blood thinner Eliquis for its strong growth. Revlimid and Eliquis tacked on double-digit growth. In response, the drug giant raised the low end of its full-year earnings outlook by a nickel.

    Among its growth products, Bristol Myers noted double-digit declines for cancer treatments Abraxane and Empliciti. Abraxane was originally developed by biotech company Celgene before its Bristol Myers takeover in late 2019.
  • S
    Sharbe
    O'Day gets paid, even though the stock drops and the rest of us suffer. Great gig for him. I wonder which yacht he's on today?
  • T
    Terry
    Remdesivir sales have been a godsend over the last few quarters, and have definitely offset the lack of growth of the other core product portfolios. Unfortunately, as Covid subsides or ebbs, Remdesivir sales will fall, and once Merck's oral therapy is approved, Remdesivir sales may plummet. This could be very damaging in the short term as GILD will no longer have the benefit of Remdesivir sales to ease the pain while waiting for the ultimate rise in sales from the Trodelvy franchise which could be a very slow rise. Unfortunately, Trodelvy (IMMN) was purchased at a very, very high price. Unless, GILD is successful in the near term in getting an oral version of Remdesivir approved (unlikely), the next several quarters could be very painful with the stock price easing below $60 once again. Longer term, perhaps much longer, GILD should be fine, and a solid value play with an attractive yield. But the Remdesivir halo is sadly on its way out. Bottom line...GILD is a decent hold for a payoff 2 to 3 years down the road. Otherwise, perhaps there are now better investment opportunities in biotech/pharma.
  • j
    jrward
    Thursday 4:13 it’s a beat!!! The conference call will produce further value with pipelines heating up!
  • L
    LostMyShirt
    These are UpTo Date Extracts. The Last one is the important one perhaps ,Quote extracts of an
    extract " remdesivir appeared to reduce hospitalizations by 87% in people at high risk of developing COVID-19." ;

    "So far, Gilead’s remdesivir is the only such drug that has received approval from the US Food and Drug Administration."

    "Molnupiravir, like remdesivir, is a nucleoside analogue, which means it mimics some of the building blocks of RNA. But the compounds work in entirely different ways. When SARS-CoV-2 enters a cell, the virus needs to duplicate its RNA genome to form new viruses. Remdesivir is a ‘chain terminator’. It stops the enzyme that builds these RNA ‘chains’ from adding further links."

    "Gilead Sciences is developing a pill version of remdesivir. And Denison suspects that if the antiviral were given to people as early as molnupiravir is — when symptoms have only just appeared and viral loads are high — it would be similarly effective. In a study presented at IDWeek, a virtual meeting of infectious-disease specialists and epidemiologists held earlier this month, researchers reported results of administering infusions of remdesivir to people in the early stages of COVID-19 every day for three days. The number of participants in the study was small, but remdesivir appeared to reduce hospitalizations by 87% in people at high risk of developing COVID-19."
  • M
    Madmonty
    Paid bashers really at it, somebody wants this friendless stock, sell and give it to them, laize faire capitalism and manipulation, the new world we live in
  • B
    Brent
    GILD's history is hitting home runs. What's next? Oral Remy?
  • J
    Jansen
    Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.
    Analysts estimate that Gilead Sciences will likely report an Earnings Per Share (EPS) of $1.74
    Gilead Sciences bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
    New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

    Historical Earnings Performance
    Last quarter the company beat on EPS by 8.09%, which was followed by a 2.21% drop in the share price the next day.
    Here's a look at Gilead Sciences's past performance and the resulting price change:

    Quarter
    Q2 2021
    Q1 2021
    Q4 2020
    Q3 2020
    EPS Estimate
    1.73
    2.09
    2.15
    1.95
    EPS Actual
    1.87
    2.08
    2.19
    2.11
    Price Change %
    -2.21%
    -0.58%
    4.0%
    -0.32%
  • S
    Sal
    Crashed at the end of the day again. Oday must be replaced